ALKERMES | ALKS - Umsatzkosten





Umsatzkosten Veränderung Datum
AbbVie USD 4.22B 329M 2026-03
Acadia Pharmaceuticals USD 24.79M 1.43M 2026-03
ALKERMES USD 73.25M 27.04M 2026-03
Amgen USD 1.6B 187M 2026-03
Biogen USD 797.5M 302M 2026-03
BioMarin Pharmaceutical USD 199.48M 37.93M 2026-03
Bristol-Myers Squibb USD 3.86B 1.07B 2026-03
Coherus Biosciences USD 4.04M 324K 2025-12
Eli Lilly USD 3.58B 205M 2026-03
Gilead Sciences USD 1.44B 174M 2026-03
Heron Therapeutics USD 11.12M 795K 2025-12
Ionis Pharmaceuticals USD 3M 5M 2026-03
J&J USD 8.07B 103M 2026-03
Merck USD 2.94B 380M 2026-03
Minerva Neurosciences 386K 31K 2024-06
Nektar Therapeutics USD 4.43M 5.3M 2024-09
Neurocrine Biosciences USD 13.8M 3.8M 2026-03
Otsuka Holdings JPY 174.09B 18.65B 2026-03
Pfizer USD 4.59B 1.7B 2026-03
Regeneron Pharmaceuticals USD 669.4M 84.8M 2026-03
Vertex Pharmaceuticals USD 392.8M 73.2M 2026-03